CSL (OTCMKTS:CSLLY) Hits New 1-Year Low on Analyst Downgrade

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price hit a new 52-week low during mid-day trading on Thursday after Royal Bank Of Canada downgraded the stock from a moderate buy rating to a hold rating. The stock traded as low as $52.00 and last traded at $54.0950, with a volume of 6737 shares traded. The stock had previously closed at $56.82.

CSLLY has been the subject of several other reports. Canaccord Genuity Group raised CSL from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 28th. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

CSL Price Performance

The business’s 50-day moving average price is $59.67 and its 200 day moving average price is $65.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.